Interstitial lung disease (ILD) is one of the common extra-articular manifestations of rheumatoid arthritis (RA) and it is associated with high mortality rate. The usual interstitial pneumonia (UIP) pattern of RA associated ILD (RA-ILD) shows some similarities to idiopathic pulmonary fibrosis, suggesting that antifibrotic therapies may have potential positive affects. In this review, we discuss the effectiveness of antifibrotic therapy for RA-ILD.
Keyphrases
- interstitial lung disease
- rheumatoid arthritis
- idiopathic pulmonary fibrosis
- systemic sclerosis
- disease activity
- ankylosing spondylitis
- pulmonary fibrosis
- randomized controlled trial
- systematic review
- cardiovascular events
- risk factors
- type diabetes
- systemic lupus erythematosus
- cardiovascular disease
- respiratory failure
- extracorporeal membrane oxygenation